ExpreS2ion Biotech Holding AB (publ)

OM:EXPRS2 Stock Report

Market Cap: SEK 61.7m

ExpreS2ion Biotech Holding Management

Management criteria checks 1/4

ExpreS2ion Biotech Holding's CEO is Bent Frandsen, appointed in Dec 2019, has a tenure of 5.17 years. directly owns 0.6% of the company’s shares, worth SEK368.65K. The average tenure of the management team and the board of directors is 4.1 years and 2.3 years respectively.

Key information

Bent Frandsen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.2yrs
CEO ownership0.6%
Management average tenure4.1yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

We're Keeping An Eye On ExpreS2ion Biotech Holding's (STO:EXPRS2) Cash Burn Rate

Mar 07
We're Keeping An Eye On ExpreS2ion Biotech Holding's (STO:EXPRS2) Cash Burn Rate

ExpreS2ion Biotech Holding (STO:EXPRS2) Shareholders Have Enjoyed A Whopping 349% Share Price Gain

Feb 08
ExpreS2ion Biotech Holding (STO:EXPRS2) Shareholders Have Enjoyed A Whopping 349% Share Price Gain

CEO Compensation Analysis

How has Bent Frandsen's remuneration changed compared to ExpreS2ion Biotech Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-SEK 36m

Sep 30 2024n/an/a

-SEK 34m

Jun 30 2024n/an/a

-SEK 45m

Mar 31 2024n/an/a

-SEK 78m

Dec 31 2023n/an/a

-SEK 91m

Sep 30 2023n/an/a

-SEK 127m

Jun 30 2023n/an/a

-SEK 136m

Mar 31 2023n/an/a

-SEK 131m

Dec 31 2022n/an/a

-SEK 119m

Sep 30 2022n/an/a

-SEK 84m

Jun 30 2022n/an/a

-SEK 63m

Mar 31 2022n/an/a

-SEK 47m

Dec 31 2021SEK 2mSEK 2m

-SEK 44m

Compensation vs Market: Insufficient data to establish whether Bent's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Insufficient data to compare Bent's compensation with company performance.

CEO

Bent Frandsen

5.2yrs

Tenure

SEK 1,962,000

Compensation

Mr. Bent U. Frandsen, MSc, has been Chief Executive Officer at ExpreS2ion Biotech Holding AB (publ) since December 20, 2019. He serves as Chief Executive Officer at ExpreS2ion Biotechnologies ApS. He serve...

Leadership Team

NamePositionTenureCompensationOwnership
Bent Frandsen
Chief Executive Officer5.2yrsSEK 1.96m0.60%
SEK 368.6k
Keith Alexander
Chief Financial Officer4.3yrsno data0.042%
SEK 25.9k
Max Sogaard
Senior Vice President of Research & Development and Technology3.9yrsno datano data
Farshad Guirakhoo
Chief Scientific Officer2.1yrsno datano data

4.1yrs

Average Tenure

Experienced Management: EXPRS2's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jakob Knudsen
Independent Director7.8yrsSEK 108.00k0.025%
SEK 15.5k
Stanley Plotkin
Member of Infectious Diseases Scientific Advisory Board1.9yrsno datano data
Mark Schleiss
Member of Infectious Diseases Scientific Advisory Board1.9yrsno datano data
Martin Jensen
Chairman of the Board15.1yrsSEK 199.00kno data
Karin Garre
Independent Director3.8yrsSEK 54.00kno data
Sara Sande
Independent Director3.8yrsSEK 54.00kno data
Giuseppe Curigliano
Member of Oncology Scientific Advisory Boardno datano datano data
Michael Andersson
Member of Oncology Scientific Advisory Board2.3yrsno datano data
Rupert Bartsch
Member of Oncology Scientific Advisory Board2.3yrsno datano data
Daniel Lenihan
Member of Oncology Scientific Advisory Board2.3yrsno datano data
Allan Thomsen
Member of Infectious Diseases Scientific Advisory Board1.9yrsno datano data
Lone Stensballe
Member of Infectious Diseases Scientific Advisory Board1.9yrsno datano data

2.3yrs

Average Tenure

64yo

Average Age

Experienced Board: EXPRS2's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:19
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ExpreS2ion Biotech Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis BerzhaninPareto Securities